Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test help understand hair loss?

NCT ID NCT07499713

Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study examines whether certain blood markers (VEGF-A and VCAM-1) are linked to nailfold capillary changes in people with alopecia areata. Researchers will compare 90 participants (patients with acute or chronic alopecia areata and healthy volunteers) using blood tests, nailfold microscopy, and scalp imaging. The goal is to better understand the role of blood vessels and inflammation in this hair loss condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward new ways to monitor or classify alopecia areata based on blood markers and capillary changes.
What could go wrong
This is an early observational study with only 90 participants, so results may not apply to everyone. It aims to understand the disease, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients diagnosed with Alopecia Areata (AA) and healthy volunteers recruited from Istanbul Education and Research Hospital, a tertiary care dermatology outpatient clinic in Istanbul. The patient group is stratified into acute and chronic phenotypes based on disease duration. The healthy control group includes age- and sex-matched individuals with no history of hair, nail, or systemic vascular diseases.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: Participants aged between 18 and 60 years. * Diagnosis: Clinical and trichoscopic diagnosis of Alopecia Areata (AA) by a dermatologist. * Categorization: "Acute" (\<6 months duration) or "Chronic" (≥6 months duration) groups. * Consent: Ability to provide written informed consent for participation in the study. Exclusion Criteria: * Medical History: Patients with a history of diabetes mellitus, autoimmune diseases, connective tissue diseases, chronic inflammatory or vascular diseases. * Pregnancy \& Lactation: Pregnancy or breastfeeding. * Lifestyle Factors: Active smoking or chronic alcohol use. * Hair \& Nail Conditions: Causes of hair loss other than alopecia areata, the presence of any nail disease, or having had a manicure within the last 3 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata Alopecia areata(AA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Education and Research Hospital

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.